CompFox AI Summary
Plaintiffs allege that defendants monopolized and attempted to monopolize the market for the gastric acid inhibiting drug Prilosec through sham litigation, violating Section 2 of the Sherman Antitrust Act and various state laws. The core allegation is that defendants listed numerous later-obtained patents in the Orange Book, knowing they would not proscribe generic versions, solely to trigger automatic 30-month stays on generic drug approvals by initiating infringement lawsuits. Defendants moved to dismiss the Amended Complaint based on the Noerr-Pennington doctrine, which provides antitrust immunity for attempts to influence governmental action. The court, presided over by District Judge Rakoff, found that because claims of infringement for four of the six asserted patents had proceeded beyond summary judgment and two to trial, the litigation was not objectively baseless and thus enjoyed Noerr-Pennington immunity. Allegations of fraud in obtaining or listing patents were dismissed due to lack of particularity as required by Fed.R.Civ.P. 9(b). The court also determined that merely listing the patents did not cause the monopoly extension; rather, it was the subsequent infringement lawsuits. Consequently, the court granted the defendants' motion to dismiss, dismissing the federal claims with prejudice and the state-law claims without prejudice due to a lack of supplemental jurisdiction.
Twin City Bakery Workers & Welfare Fund v. Astra Aktiebolag is a workers' compensation case decided in District Court, S.D. New York. This case addresses legal issues related to compensation claims, benefits, and court rulings.
It is commonly referenced in legal research involving workers' compensation laws in District Court, S.D. New York.
Full Decision Text1 Pages
Plaintiffs allege that defendants monopolized and attempted to monopolize the market for the gastric acid inhibiting drug Prilosec through "sham" litigation, violating Section 2 of the Sherman Antitrust Act and various state laws. The core allegation is that defendants listed numerous later-obtained patents in the Orange Book, knowing they would not proscribe generic versions, solely to trigger automatic 30-month stays on generic drug approvals by initiating infringement lawsuits. Defendants moved to dismiss the Amended Complaint based on the Noerr-Pennington doctrine, which provides antitrust immunity for attempts to influence governmental action. The court, presided over by District Judge Rakoff, found that because claims of infringement for four of the six asserted patents had proceeded beyond summary judgment and two to trial, the litigation was not objectively baseless and thus enjoyed Noerr-Pennington immunity. Allegations of fraud in obtaining or listing patents were dismissed due to lack of particularity as required by Fed.R.Civ.P. 9(b). The court also determined that merely listing the patents did not cause the monopoly extension; rather, it was the subsequent infringement lawsuits. Consequently, the court granted the defendants' motion to dismiss, dismissing the federal claims with prejudice and the state-law claims without prejudice due to a lack of supplemental jurisdiction.
Read the full decision
Join + legal professionals. Create a free account to access the complete text of this decision and search our entire database.